Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Combination of Pan-Histone Deacetylase Inhibitor and Autophagy Inhibitor Exerts Superior Efficacy against Triple-Negative Human Breast Cancer Cells

Rekha Rao, Ramesh Balusu, Warren Fiskus, Uma Mudunuru, Sreedhar Venkannagari, Lata Chauhan, Jacqueline E. Smith, Stacey L. Hembruff, Kyungsoo Ha, Peter Atadja, Kapil N. Bhalla

Mol Cancer Ther (2012) 11 (4): 973–983.

https://doi.org/10.1158/1535-7163.MCT-11-0979

Published: 08 April 2012

View articletitled, Combination of Pan-Histone Deacetylase Inhibitor and Autophagy Inhibitor Exerts Superior Efficacy against Triple-Negative Human Breast Cancer Cells

Includes: Supplementary data

Journal Articles

Treatment with Panobinostat Induces Glucose-Regulated Protein 78 Acetylation and Endoplasmic Reticulum Stress in Breast Cancer Cells

Rekha Rao, Srilatha Nalluri, Ravindra Kolhe, Yonghua Yang, Warren Fiskus, Jianguang Chen, Kyungsoo Ha, Kathleen M. Buckley, Ramesh Balusu, Veena Coothankandaswamy, Atul Joshi, Peter Atadja, Kapil N. Bhalla

Mol Cancer Ther (2010) 9 (4): 942–952.

https://doi.org/10.1158/1535-7163.MCT-09-0988

Published: 07 April 2010

View articletitled, Treatment with Panobinostat Induces Glucose-Regulated Protein 78 Acetylation and Endoplasmic Reticulum Stress in Breast Cancer Cells

Journal Articles

Abstract C196: Co‐treatment with NVP‐BEZ235 and heat shock protein (hsp) 90 or pan‐deacetylase (DAC) inhibitor is synergistically active against non‐small cell lung cancer (NSCLC) cells with mutant RAS and LKB1

Sunil Upadhyay, Warren C. Fiskus, Rekha Rao, Atul Joshi, Sanjay Koul, Ramesh Balusu, Uma Mudunuru, Kathleen M. Buckley, Cornelia Quadt, Peter Atadja, Carlos Garcia‐Echeverria, Kapil N. Bhalla

Mol Cancer Ther (2009) 8 (12_Supplement): C196.

https://doi.org/10.1158/1535-7163.TARG-09-C196

Published: 10 December 2009

View articletitled, Abstract C196: Co‐treatment with NVP‐BEZ235 and heat shock protein (hsp) 90 or pan‐deacetylase (DAC) inhibitor is synergistically active against non‐small cell lung cancer (NSCLC) cells with mutant RAS and LKB1

Journal Articles

Abstract B176: Synergistic induction of apoptosis by the histone‐deacetylase inhibitor, Panobinostat, combined with ABT‐737 or rhTRAIL, in multiple myeloma

Geoffrey M. Matthews, Jake Shortt, Kellie M. Banks, Kym Stanley, David Faulkner, Leif Bergsagel, Marta Chesi, Peter Atadja, Ricky W. Johnstone

Mol Cancer Ther (2009) 8 (12_Supplement): B176.

https://doi.org/10.1158/1535-7163.TARG-09-B176

Published: 10 December 2009

View articletitled, Abstract B176: Synergistic induction of apoptosis by the histone‐deacetylase inhibitor, Panobinostat, combined with ABT‐737 or rhTRAIL, in multiple myeloma

Journal Articles

Abstract B21: Targeting autophagy induced by pan‐HDAC inhibitor panobinostat and promoted by acetylated hsp70: A novel therapy for breast cancer

Rekha Rao, Warren C. Fiskus, Yonghua Yang, Uma Mudunuru, Yongchao Wang, Peter Atadja, Kapil N. Bhalla

Mol Cancer Ther (2009) 8 (12_Supplement): B21.

https://doi.org/10.1158/1535-7163.TARG-09-B21

Published: 10 December 2009

View articletitled, Abstract B21: Targeting autophagy induced by pan‐HDAC inhibitor panobinostat and promoted by acetylated hsp70: A novel therapy for breast cancer

Journal Articles

Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions

Roberto R. Rosato, Jorge A. Almenara, Sonia C. Maggio, Stefanie Coe, Peter Atadja, Paul Dent, Steven Grant

Mol Cancer Ther (2008) 7 (10): 3285–3297.

https://doi.org/10.1158/1535-7163.MCT-08-0385

Published: 13 October 2008

View articletitled, Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions

Includes: Supplementary data

Journal Articles

Characterization of the apoptotic and therapeutic activities of the histone deacetylase inhibitors LAQ824 and LBH589 using a mouse model of B cell lymphoma.

Leigh Ellis, Ralph Lindemann, Andrea Newbold, Kate Whitecross, Leonie Cluse, Marc Pelligrini, Andrew Wei, Clare Scott, Peter Atadja, Scott Lowe, Ricky Johnstone

Mol Cancer Ther (2007) 6 (11_Supplement): B132.

Published: 01 November 2007

View articletitled, Characterization of the apoptotic and therapeutic activities of the histone deacetylase inhibitors LAQ824 and LBH589 using a mouse model of B cell lymphoma.

Journal Articles

Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor–dependent human lung cancer cells

Arthur Edwards, Jiannong Li, Peter Atadja, Kapil Bhalla, Eric B. Haura

Mol Cancer Ther (2007) 6 (9): 2515–2524.

https://doi.org/10.1158/1535-7163.MCT-06-0761

Published: 17 September 2007

View articletitled, Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor–dependent human lung cancer cells

Journal Articles

Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma

Yukihiko Kato, Brenda C. Salumbides, Xiao-Fei Wang, David Z. Qian, Simon Williams, Yongfeng Wei, Tolib B. Sanni, Peter Atadja, Roberto Pili

Mol Cancer Ther (2007) 6 (1): 70–81.

https://doi.org/10.1158/1535-7163.MCT-06-0125

Published: 19 January 2007

View articletitled, Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma

Journal Articles

Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells

Warren Fiskus, Michael Pranpat, Maria Balasis, Bryan Herger, Rekha Rao, Arul Chinnaiyan, Peter Atadja, Kapil Bhalla

Mol Cancer Ther (2006) 5 (12): 3096–3104.

https://doi.org/10.1158/1535-7163.MCT-06-0418

Published: 15 December 2006

View articletitled, Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells

Journal Articles

Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells

Roberto R. Rosato, Jorge A. Almenara, Sonia C. Maggio, Peter Atadja, Ruth Craig, Julie Vrana, Paul Dent, Steven Grant

Mol Cancer Ther (2005) 4 (11): 1772–1785.

https://doi.org/10.1158/1535-7163.MCT-05-0157

Published: 07 November 2005

View articletitled, Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells

Journal Articles

Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824

Liwei Chen, Songshu Meng, Hai Wang, Purva Bali, Wenlong Bai, Benyi Li, Peter Atadja, Kapil N. Bhalla, Jie Wu

Mol Cancer Ther (2005) 4 (9): 1311–1319.

https://doi.org/10.1158/1535-7163.MCT-04-0287

Published: 16 September 2005

View articletitled, Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824

Journal Articles

Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B

Lianne Fuino, Purva Bali, Sylvie Wittmann, Sreenivas Donapaty, Fei Guo, Hirohito Yamaguchi, Hong-Gang Wang, Peter Atadja, Kapil Bhalla

Mol Cancer Ther (2003) 2 (10): 971–984.

Published: 24 October 2003

View articletitled, Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Combination of Pan-Histone Deacetylase Inhibitor and Autophagy Inhibitor Exerts Superior Efficacy against Triple-Negative Human Breast Cancer Cells

Treatment with Panobinostat Induces Glucose-Regulated Protein 78 Acetylation and Endoplasmic Reticulum Stress in Breast Cancer Cells

Abstract C196: Co‐treatment with NVP‐BEZ235 and heat shock protein (hsp) 90 or pan‐deacetylase (DAC) inhibitor is synergistically active against non‐small cell lung cancer (NSCLC) cells with mutant RAS and LKB1

Abstract B176: Synergistic induction of apoptosis by the histone‐deacetylase inhibitor, Panobinostat, combined with ABT‐737 or rhTRAIL, in multiple myeloma

Abstract B21: Targeting autophagy induced by pan‐HDAC inhibitor panobinostat and promoted by acetylated hsp70: A novel therapy for breast cancer

Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions

Characterization of the apoptotic and therapeutic activities of the histone deacetylase inhibitors LAQ824 and LBH589 using a mouse model of B cell lymphoma.

Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor–dependent human lung cancer cells

Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma

Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells

Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells

Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824

Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only